Amylyx Pharmaceuticals, Inc.AMLXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P17
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | -13.14% |
| 2024 | -18.80% |
| 2023 | 37.17% |
| 2022 | 112.19% |
| 2021 | 79.07% |
| 2020 | 106.69% |
| 2019 | 0.00% |